Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Embolotherapy Strategy Insights and Market Forecast to 2033 - Healthcare Facilities Under Pressure to Adopt Next-Gen Embolotherapy for Better Outcomes - ResearchAndMarkets.com

businesswire.com
PEN Penumbra, Inc. received FDA clearance for its Ruby XL System, which enhances embolization efficiency and patient outcomes, indicating positive market reception and potential for growth in the embolotherapy sector.

DUBLIN--( BUSINESS WIRE)--The "Embolotherapy Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering.

The global embolotherapy market is forecasted to grow from USD 3.16 billion in 2024 to USD 5.82 billion by 2033, at a CAGR of 6.99% from 2025 to 2033. This growth is driven by the increasing prevalence of cancer, vascular disorders, and trauma cases, fueling the demand for minimally invasive treatments.

Innovations in embolic agents such as drug-eluting beads, liquid embolics, and bioresorbable microspheres, along with advanced delivery devices like microcatheters and flow diverters, have enhanced procedural accuracy and outcomes. A surge in patient preference for procedures offering quicker recovery, improved healthcare infrastructure in emerging markets, and supportive regulatory policies further propel market growth.

The rise in cancer treatments, trauma cases, and vascular disorders increases demand for embolotherapy. Healthcare facilities are experiencing a surge in procedure volumes, necessitating the adoption of effective embolic agents and delivery systems. To address these needs, the focus is shifting towards next-gen embolotherapy technologies, which enable faster, precise procedures with fewer complications.

In June 2025, Penumbra, Inc. introduced the Ruby XL System, following FDA clearance. It offers efficiency in embolizations, potentially reducing radiation exposure and enhancing outcomes, especially for large vessel and high-flow procedures.

Cancer and vascular diseases are key drivers of the embolotherapy industry as they often require targeted treatments. Embolotherapy is used in managing liver cancer through transarterial embolization, controlling bleeding, shrinking tumors, and preserving healthy tissues. Conditions such as arteriovenous malformations and gastrointestinal bleeding also see increased management through embolotherapy, offering an effective alternative to surgery.

According to WHO, liver and intrahepatic bile duct cancer cases are expected to rise from 2022 to 2040, illustrating the growing need for embolotherapy solutions.

Global Embolotherapy Market Report Segmentation

This report provides a detailed revenue forecast at global, regional, and country levels and analyzes the latest industry trends across various segments from 2021 to 2033.

Product Outlook (Revenue, USD Million, 2021-2033)

Application Outlook (Revenue, USD Million, 2021-2033)

End Use Outlook (Revenue, USD Million, 2021-2033)

Regional Outlook (Revenue, USD Million, 2021-2033)

Why You Should Buy This Report

Report Deliverables

Key Attributes

The companies profiled in this Embolotherapy market report include:

For more information about this report visit https://www.researchandmarkets.com/r/zc5n62

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.